26424395|t|Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.
26424395|a|BACKGROUND: Cholinergic transmission loss is one of the major features in Alzheimer&amp;#039;s Disease (AD). Acetylcholinesterase inhibitors (AChEI) are moderately active in AD. alpha7nAChR (alpha-7 nicotinic acetylcholine receptor), encoded by CHRNA7 (Nicotinic Cholinergic Receptor Alpha-7 gene), is involved in the cholinergic neurotransmission and AD pathogenesis. alpha7nAChR is a putative receptor of amyloid beta (Abeta). The complex alpha7nAChR-Abeta is found in neuritic plaques and AD cortical neurons. In normal physiologic conditions, alpha7nAChR-Abeta interaction leads to receptor activation. Genetic polymorphisms (SNPs) of CHRNA7 and/or CHRFAM7A (fusion gene containing CHRNA7 partial duplication) may be a possible susceptibility trait to dementia, potentially useful to identify high risk or responder individuals. CHRFAM7A-2-bp deletion or CHRNA7 SNPs (rs1514246, rs2337506, rs8027814) seem protective factors in different forms of dementia including AD. OBJECTIVE: Correlation between(SNPs) of CHRNA7 and/or CHRFAM7A and cholinesterase inhibitors in AD. METHODS: Literature review. RESULTS: Among the leading AD therapeutics, Donepezil (DP) and galantamine (AChEI) induce upregulation of alpha7nAChR protein levels, protecting neurons from degeneration. Patients carrying rs8024987 (C/G) or rs6494223 (C/T) respond better to AChEI. In the caucasic population rs6494223 TT subjects are 7-15% of the total. alpha7nAChR upregulation induced by DP is higher in lymphocytes from TT subjects than in CC or CT as well as calcium uptake. CONCLUSION: The correlation between genetic and functionality data may have an impact on several aspects of disease presentation and therapy, helping in prediction pattern of AD presentation and treatment efficacy. As a consequence it may lead to better patients quality of life and longer periods of self- sufficiency. Moreover, it may contribute to clarify AChEI mechanisms of action.
26424395	42	48	CHRNA7	Gene	1139
26424395	112	120	Patients	Species	9606
26424395	126	145	Alzheimer's Disease	Disease	MESH:D000544
26424395	221	249	Alzheimer&amp;#039;s Disease	Disease	MESH:D000544
26424395	251	253	AD	Disease	MESH:D000544
26424395	321	323	AD	Disease	MESH:D000544
26424395	338	378	alpha-7 nicotinic acetylcholine receptor	Gene	1139
26424395	392	398	CHRNA7	Gene	1139
26424395	499	501	AD	Disease	MESH:D000544
26424395	568	573	Abeta	Gene	351
26424395	600	605	Abeta	Gene	351
26424395	639	641	AD	Disease	MESH:D000544
26424395	706	711	Abeta	Gene	351
26424395	786	792	CHRNA7	Gene	1139
26424395	800	808	CHRFAM7A	Gene	89832
26424395	833	839	CHRNA7	Gene	1139
26424395	903	911	dementia	Disease	MESH:D003704
26424395	980	988	CHRFAM7A	Gene	89832
26424395	1006	1012	CHRNA7	Gene	1139
26424395	1019	1028	rs1514246	SNP	tmVar:rs1514246;VariantGroup:4;RS#:1514246
26424395	1030	1039	rs2337506	SNP	tmVar:rs2337506;VariantGroup:0;CorrespondingGene:1139;RS#:2337506;CorrespondingSpecies:9606
26424395	1041	1050	rs8027814	SNP	tmVar:rs8027814;VariantGroup:2;CorrespondingGene:1139;RS#:8027814;CorrespondingSpecies:9606
26424395	1098	1106	dementia	Disease	MESH:D003704
26424395	1117	1119	AD	Disease	MESH:D000544
26424395	1161	1167	CHRNA7	Gene	1139
26424395	1175	1183	CHRFAM7A	Gene	89832
26424395	1217	1219	AD	Disease	MESH:D000544
26424395	1276	1278	AD	Disease	MESH:D000544
26424395	1293	1302	Donepezil	Chemical	MESH:D000077265
26424395	1304	1306	DP	Chemical	MESH:D000077265
26424395	1312	1323	galantamine	Chemical	MESH:D005702
26424395	1421	1429	Patients	Species	9606
26424395	1439	1448	rs8024987	SNP	tmVar:rs8024987;VariantGroup:1;CorrespondingGene:1139;RS#:8024987;CorrespondingSpecies:9606
26424395	1450	1453	C/G	DNAMutation	tmVar:c|SUB|C||G;VariantGroup:1;CorrespondingGene:1139;RS#:8024987;CorrespondingSpecies:9606
26424395	1458	1467	rs6494223	SNP	tmVar:rs6494223;VariantGroup:3;CorrespondingGene:1139;RS#:6494223;CorrespondingSpecies:9606
26424395	1469	1472	C/T	DNAMutation	tmVar:c|SUB|C||T;VariantGroup:3;CorrespondingGene:1139;RS#:6494223;CorrespondingSpecies:9606
26424395	1526	1535	rs6494223	SNP	tmVar:rs6494223;VariantGroup:3;CorrespondingGene:1139;RS#:6494223;CorrespondingSpecies:9606
26424395	1608	1610	DP	Chemical	MESH:D000077265
26424395	1681	1688	calcium	Chemical	MESH:D002118
26424395	1872	1874	AD	Disease	MESH:D000544
26424395	1951	1959	patients	Species	9606
26424395	Negative_Correlation	MESH:D003704	RS#:2337506;CorrespondingGene:1139
26424395	Negative_Correlation	MESH:D000544	RS#:8027814;CorrespondingGene:1139
26424395	Negative_Correlation	MESH:D005702	MESH:D000544
26424395	Association	MESH:D003704	1139
26424395	Negative_Correlation	MESH:D003704	RS#:8027814;CorrespondingGene:1139
26424395	Negative_Correlation	MESH:D003704	RS#:1514246
26424395	Negative_Correlation	MESH:D000544	RS#:1514246
26424395	Association	MESH:D000544	1139
26424395	Association	MESH:D003704	89832
26424395	Negative_Correlation	MESH:D000544	89832
26424395	Negative_Correlation	MESH:D000544	RS#:2337506;CorrespondingGene:1139
26424395	Association	MESH:D000544	351
26424395	Negative_Correlation	MESH:D000077265	MESH:D000544
26424395	Association	MESH:D003704	1139
26424395	Association	MESH:D000544	1139

